Faeth Therapeutics, Inc.
corporate_fare Company Profile
Faeth Therapeutics, Inc. (NASDAQ:FTH) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 7 items for FTH at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 7 most recent items scored 7 or higher, the top rating is 8/10, with 1 rated 8 or above. Recent SEC coverage for FTH spans 10-Q, 8-K.
Recent high-impact activity:
- Faeth Lands Roche Collaboration to Test PIKTOR With Giredestrant in Breast Cancer
- PIKTOR Hits 33% Confirmed Response Rate in Advanced Endometrial Cancer Phase 2
- Faeth 10-Q: $174.8M Cash Funds PIKTOR Trials Through Topline Data
- Faeth Posts $20.4M Q3 Loss, Cash at $174.8M Ahead of Year-End PIKTOR Data
- FDA Grants Fast Track to Faeth's Piktor Combo in Endometrial Cancer
Financial Snapshot
Short Interest & Short Volume
6.31 days to coverFINRA reported short interest of 2,730,889 shares in FTH as of the October 30, 2026 settlement, a 17.7% increase from the prior period — about 6.3 days to cover at its recent average daily volume. On November 20, 2026, 65.8% of FTH volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.